Stock Comparison
IFRX vs JNJ
InflaRx NV vs Johnson & Johnson
Who's the better investment? Let's break it down.
The Verdict
IFRX takes this one.
It's not even close. IFRX outscores JNJ by 3.0 points. That's a significant gap in our deep value framework.
Want to compare any two stocks?
Sign up free — get 3 DVR analyses/day, 1800+ stocks, portfolio roast. No credit card.
Valuation
IFRX
Metric
JNJ
Market Cap
P/E Ratio
Lower may indicate better value
Forward P/E
Price/Book
Profitability & Growth
IFRX
Metric
JNJ
Profit Margin
Gross Margin
Operating Margin
Return on Equity
Return on Assets
Revenue Growth
EPS
Financial Health
IFRX
Metric
JNJ
Debt-to-Equity
Lower = less leverage
Current Ratio
Above 1.0 is healthy
Beta
Lower = less volatile
Dividend Yield
Risk Comparison
IFRX
JNJ
What Could Go Wrong
The biggest risk for JNJ, despite its broad diversification, remains its exposure to patent expirations and increasing biosimilar competition for blockbuster drugs like Stelara, which generated over $...
Red Flags
- 🚩Deceleration of organic revenue growth below 4% for two consecutive quarters, signaling broader mark...
- 🚩Significant increase in litigation provisions or adverse judgments exceeding $5 billion in a single ...
- 🚩Dividend growth rate significantly slowing or pausing, indicating a fundamental shift in capital all...
Competitive Moat
IFRX
Rating
🛡️ Narrow
Trend
➡️ Stable but vulnerable
JNJ
Rating
🛡️ Wide
Trend
➡️ Stable
Investment Thesis
InflaRx represents an extremely high-risk, high-reward investment focused on the successful commercialization of its EU-approved orphan drug, Gohibic, for ANCA-associated vasculitis. Despite a clear market opportunity and unique drug profile, the company faces immediate existential financial challenges due to a critically short cash runway and slow sales uptake. A successful, non-dilutive financin...
Full IFRX AnalysisIf Johnson & Johnson continues to deliver consistent mid-single-digit organic revenue growth, driven by key pharmaceutical products and strategic MedTech innovation, while maintaining its strong dividend and capital allocation discipline, then its valuation should remain stable or grow modestly, providing a reliable long-term investment for income and capital preservation. This thesis focuses on s...
Full JNJ AnalysisPrice Targets & Strategy
Price Targets & Entry/Exit Strategy
Sign up free to unlock the full comparison
Growth Catalysts
Growth Catalysts Comparison
Sign up free to unlock the full comparison
Market Sentiment
Market Sentiment Analysis
Sign up free to unlock the full comparison
The Deep Dive
InflaRx (IFRX) remains a highly speculative, high-risk, high-reward biotech play with theoretical 10x potential if critical hurdles are overcome. The EU-approved orphan drug, Gohibic, for ANCA-associated vasculitis offers a strong market opportunity and a unique mechanism of action. However, the company's financial health is critically weak, with an estimated cash runway of 7-10 months remaining from March 2026. Commercialization of Gohibic continues to be slower than required to achieve self-su...
Full IFRX AnalysisJohnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555.59 billion fundamentally restricts its ability to achieve 10x growth within a 3-5 year timeframe. Su...
Full JNJ AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.